U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18N4O2.CH4O3S
Molecular Weight 394.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIRIBEDIL MESYLATE

SMILES

CS(O)(=O)=O.C(N1CCN(CC1)C2=NC=CC=N2)C3=CC=C4OCOC4=C3

InChI

InChIKey=DEZKFCIOSKCCHK-UHFFFAOYSA-N
InChI=1S/C16H18N4O2.CH4O3S/c1-4-17-16(18-5-1)20-8-6-19(7-9-20)11-13-2-3-14-15(10-13)22-12-21-14;1-5(2,3)4/h1-5,10H,6-9,11-12H2;1H3,(H,2,3,4)

HIDE SMILES / InChI

Molecular Formula C16H18N4O2
Molecular Weight 298.3397
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Piribedil is an antiparkinsonian agent which acts as D2 and D3 receptor agonist. In European countries and worldwide it is used as a monotherapy or in combination with dopatherapy for treatment of Parkinson's disease, cognitive impairment and obliterating arteriopathy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P35462
Gene ID: 1814.0
Gene Symbol: DRD3
Target Organism: Homo sapiens (Human)
Target ID: P14416
Gene ID: 1813.0
Gene Symbol: DRD2
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
TRIVASTAL

Approved Use

Adjunctive treatment of intermittent claudication in chronic obliterating arteriopathies of the lower limbs (in stage 2).
Palliative
TRIVASTAL

Approved Use

Adjunctive symptomatic treatment of chronic pathological cognitive and neurosensorial deficit in elderly subjects (excluding Alzheimer's disease and other dementia).
Primary
TRIVASTAL

Approved Use

Treatment of Parkinson's disease: either as monotherapy (treatment of forms with predominant tremor), or in association with dopatherapy from the outset, or secondarily, particularly in forms with tremor.
PubMed

PubMed

TitleDatePubMed
Parkinsonism by haloperidol and piribedil.
1978 Oct 31
Sleep attacks and Parkinson's disease treatment.
2000 Apr 15
Discriminative stimulus properties of the dopamine D3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D3 versus D2 receptors.
2000 Feb 14
Pharmacological treatment for aphasia following stroke.
2001
[Use of dopamine analogs in Parkinson's disease treatment].
2002
DA agonists -- non-ergot derivatives: piribedil: management of Parkinson's disease.
2002
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
2002
[Alpha-2 adrenergic receptors and Parkinson's disease].
2002 Jul 27
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
2002 Nov
Age-related mild cognitive deficit: a ready-to-use concept?
2003 Mar
[Clinical and stabilometric analysis of postural instability in Parkinson's disease].
2004
Drugs in development for Parkinson's disease.
2004 Jul
Drug treatment of Parkinson's disease.
2004 Sep
[An impact of pronoran on cognitive and affective disorders in Parkinson's disease].
2005
End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
2005 Jul
Chemically modified carbon paste electrode for the potentiometric flow injection analysis of piribedil in pharmaceutical preparation and urine.
2005 Jul 15
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
2005 May
The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
2006 Apr
Activation of D2-like receptors induces sympathetic climactic-like responses in male and female anaesthetised rats.
2006 Jun
Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
2006 May-Jun
Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
2006 Nov
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
2006 Nov
[Cognitive disturbances and dysfunction of neuromediator systems in cerebral vascular insufficiency after treatment with pronoran].
2007
Identification of amino acid determinants of dopamine 2 receptor synthetic agonist function.
2007 Apr
About the anti-Parkinson equivalency of levodopa and dopamine agonists.
2007 Jan-Feb
Hallucinations: Etiology and clinical implications.
2009 Jul
From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
2010 Nov
Patents

Patents

Sample Use Guides

For the treatment of Parkinson's disease as a monotherapy, piribedil should be administered orally at 150 to 250 mg.
Route of Administration: Oral
Binding of piribedil to D2, D3 and D4 receptors was measured using [3H]spiperone as a radiolabel. Coronal sections from rat brains were cut at the level of the anterior caudate-putame. The sections were thaw-mounted on gelatin-coated glass slides. Sections were incubated for 5 min in a 50mM Tris-HCl buffer, then were incubated for 30 min at room temperature in the incubation buffer. Piribedil was tested in vitro at 5 different concentrations, from 10 uM to 1 nM.
Substance Class Chemical
Created
by admin
on Wed Jul 05 23:15:45 UTC 2023
Edited
by admin
on Wed Jul 05 23:15:45 UTC 2023
Record UNII
1U37NGM6KK
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIRIBEDIL MESYLATE
Common Name English
PIRIBEDIL MONOMETHYLSULFONATE
Common Name English
2-(4-(1,3-BENZODIOXOL-5-YLMETHYL)PIPERAZIN-1-YL)PYRIMIDINE, METHANESULFONIC ACID
Common Name English
PIRIBEDIL MONOMETHANESULFONATE
WHO-DD  
Common Name English
ET-495 METHANESULFONATE
Common Name English
Piribedil monomethanesulfonate [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
198284
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
EPA CompTox
DTXSID30200314
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
RXCUI
236380
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY RxNorm
EVMPD
SUB21569
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
CAS
52293-23-9
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
ECHA (EC/EINECS)
257-818-8
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
SMS_ID
100000088389
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
FDA UNII
1U37NGM6KK
Created by admin on Wed Jul 05 23:15:45 UTC 2023 , Edited by admin on Wed Jul 05 23:15:45 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY